New RNA drug takes on tough liver tumors
NCT ID NCT07580261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 people with advanced liver cancer that has stopped responding to standard treatments. The drug is designed to boost the immune system by blocking two cancer defenses at once. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YMN-A02 (a bifunctional RNA agent that produces a CTLA-4 antibody and TGF-β blocker)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that doesn't respond to current therapies.
What could go wrong
This is a very early Phase 1 trial with only 10 people, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••